ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, 13) is an enzyme mainly synthesized in hepatic stellate cells and also in endothelial cells. 1,2 ADAMTS13 plays a key ...

For Takeda, rusfertide adds to an emerging portfolio in rare blood disorders currently headed by recently-approved Adzynma (recombinant ADAMTS13) for clotting disorder congenital thrombotic ...

It has chalked up a series of other FDA approvals in the last few months, however, including congenital thrombotic thrombocytopenic purpura (cTTP) therapy Adzynma (ADAMTS13, recombinant ...

These were the result of mutations in the gene that encodes the protease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif 13), which cleaves von Willebrand factor (3, 4).

A great way to meet new people and share your skills – we'd love for you to join our team ...

The 2025 ACVIM Resident Research Abstract Award winners and their recognized works are as follows: Cassidy M. Coats, DVM; ...

Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many years of investigation ...

The study presents extensive gene expression profiling and bioinformatic analyses, offering insights into the roles of fibroblasts in cardiac development. The large volume of scRNA-seq data is both ...